Atossa Therapeutics (MEX:ATOS) Land And Improvements : MXN0.00 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Atossa Therapeutics Land And Improvements?

Atossa Therapeutics's land and improvements for the quarter that ended in Dec. 2024 was MXN0.00 Mil.

Atossa Therapeutics Land And Improvements Historical Data

The historical data trend for Atossa Therapeutics's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Land And Improvements Chart

Atossa Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Land And Improvements

Get a 7-Day Free Trial

Atossa Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Atossa Therapeutics Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Atossa Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (MEX:ATOS) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

ATOS:USA YAG2:Germany YAG2:Germany

Address

10202 Fifth Avenue NE, Suite 200, Seattle, WA, USA, 98125

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.